Et stort (532 patienter) forsøg er på vej og starter rekruttering i februar. Der er tale om refrac cll patienter der dog ikke har gået rotuxian endnu.
Trial Identifier: NCT01039376
http://clinicaltrials.gov/ct2/show/NCT01039376?term=CLL&recr=Open&rcv_d=14
Ja. Hvis nogen måtte tro, at der ikke sker noget nyt omkring Ofatumumab, så tager de da i den grad fejl....
Rank Status Study
1 Active, not recruiting
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in Rheumatoid Arthritis (RA) Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403 Condition: Arthritis, Rheumatoid
Intervention: Drug: Ofatumumab
2 Not yet recruiting
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: RITUXIMAB + DHAP; Drug: RITUXIMAB + DVD; Drug: OFATUMUMAB + DVD; Drug: OFATUMUMAB + DHAP
3 Active, not recruiting
Ofatumumab Dose-finding in RRMS Patients Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: ofatumumab/placebo
4 Not yet recruiting
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Conditions: Hematopoietic/Lymphoid Cancer; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Drug: cyclophosphamide; Biological: ofatumumab; Procedure: laboratory biomarker analysis; Other: flow cytometry; Genetic: protein expression analysis
5 Enrolling by invitation
Ofatumumab Retreatment and Maintenance Treatment in CLL Patients Condition: B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
6 Not yet recruiting
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Biological: Ofatumumab
7 Not yet recruiting
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
8 Active, not recruiting
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia Conditions: Follicular Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab injection vial
9 Recruiting
Phase II Study of Ofatumumab Plus ICE or DHAP Chemotherapy Regimen in Relapsed/ Refractory DLBCL Conditions: Diffuse Large B Cell Lymphoma (DLBCL); Non-Hodgkin's Lymphoma; Grade 3b Follicular Lymphoma; Transformed Follicular Lymphoma
Interventions: Drug: ofatumumab + DHAP; Drug: ofatumumab + ICE
10 Active, not recruiting
Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to MTX Therapy Conditions: Arthritis, Rheumatoid; Rheumatoid Arthritis
Interventions: Drug: Ofatumumab; Drug: Placebo
11 Recruiting
Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to TNF-? Antagonist Therapy Conditions: Arthritis, Rheumatoid; Rheumatoid Arthritis
Interventions: Drug: Ofatumumab; Drug: Placebo
12 Active, not recruiting
Ofatumumab (Humax-CD20) With CHOP in FL Patients Condition: Follicular Lymphoma
Intervention: Drug: Ofatumumab
13 Recruiting
Ofatumumab + Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
14 Recruiting
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia
Intervention: Biological: Ofatumumab
15 Not yet recruiting
Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Lenalidomide; Drug: Ofatumumab
16 Active, not recruiting
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: Ofatumumab
17 Active, not recruiting
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients Condition: B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
18 Active, not recruiting
HuMax-CD20 in Follicular Lymphoma (FL) Patients Refractory to Rituximab Condition: Follicular Lymphoma
Intervention: Drug: Ofatumumab-HuMax-CD20
19 Recruiting
Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
20 Completed
Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients Condition: Rheumatoid Arthritis
Interventions: Drug: ofatumumab; Other: placebo
Rank Status Study
1 Active, not recruiting
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in Rheumatoid Arthritis (RA) Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403 Condition: Arthritis, Rheumatoid
Intervention: Drug: Ofatumumab
2 Not yet recruiting
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: RITUXIMAB + DHAP; Drug: RITUXIMAB + DVD; Drug: OFATUMUMAB + DVD; Drug: OFATUMUMAB + DHAP
3 Active, not recruiting
Ofatumumab Dose-finding in RRMS Patients Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: ofatumumab/placebo
4 Not yet recruiting
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Conditions: Hematopoietic/Lymphoid Cancer; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Drug: cyclophosphamide; Biological: ofatumumab; Procedure: laboratory biomarker analysis; Other: flow cytometry; Genetic: protein expression analysis
5 Enrolling by invitation
Ofatumumab Retreatment and Maintenance Treatment in CLL Patients Condition: B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
6 Not yet recruiting
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Biological: Ofatumumab
7 Not yet recruiting
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
8 Active, not recruiting
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia Conditions: Follicular Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab injection vial
9 Recruiting
Phase II Study of Ofatumumab Plus ICE or DHAP Chemotherapy Regimen in Relapsed/ Refractory DLBCL Conditions: Diffuse Large B Cell Lymphoma (DLBCL); Non-Hodgkin's Lymphoma; Grade 3b Follicular Lymphoma; Transformed Follicular Lymphoma
Interventions: Drug: ofatumumab + DHAP; Drug: ofatumumab + ICE
10 Active, not recruiting
Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to MTX Therapy Conditions: Arthritis, Rheumatoid; Rheumatoid Arthritis
Interventions: Drug: Ofatumumab; Drug: Placebo
11 Recruiting
Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to TNF-? Antagonist Therapy Conditions: Arthritis, Rheumatoid; Rheumatoid Arthritis
Interventions: Drug: Ofatumumab; Drug: Placebo
12 Active, not recruiting
Ofatumumab (Humax-CD20) With CHOP in FL Patients Condition: Follicular Lymphoma
Intervention: Drug: Ofatumumab
13 Recruiting
Ofatumumab + Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
14 Recruiting
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia
Intervention: Biological: Ofatumumab
15 Not yet recruiting
Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Lenalidomide; Drug: Ofatumumab
16 Active, not recruiting
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: Ofatumumab
17 Active, not recruiting
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients Condition: B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
18 Active, not recruiting
HuMax-CD20 in Follicular Lymphoma (FL) Patients Refractory to Rituximab Condition: Follicular Lymphoma
Intervention: Drug: Ofatumumab-HuMax-CD20
19 Recruiting
Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
20 Completed
Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients Condition: Rheumatoid Arthritis
Interventions: Drug: ofatumumab; Other: placebo
